Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma

Abstract

<div class="section"> <a class="named-anchor" id="S1"> <!-- named anchor --> </a> <h5 class="title" id="d606809e219">Objective</h5> <p id="P1">To estimate whether gastrointestinal-type chemotherapy was associated with improved survival compared to standard gynecologic regimens for women with ovarian mucinous carcinoma. </p> </div><div class="section"> <a class="named-anchor" id="S2"> <!-- named anchor --> </a> <h5 class="title" id="d606809e224">Methods</h5> <p id="P2">We conducted a retrospective cohort study of patients with ovarian mucinous carcinoma who received postoperative adjuvant chemotherapy at two academic centers. Demographic and clinical information was abstracted from the medical records. Gastrointestinal-type chemotherapy contained 5-fluorouracil, capecitabine, irinotecan, or oxaliplatin. Gynecologic regimens included standard carboplatin or cisplatin. Bevacizumab treatment was allowed in both groups. Summary statistics were used to compare baseline characteristics; Kaplan-Meier product-limit estimator was used to compare survival outcomes. </p> </div><div class="section"> <a class="named-anchor" id="S3"> <!-- named anchor --> </a> <h5 class="title" id="d606809e229">Results</h5> <p id="P3">Fifty-two patients received either gastrointestinal-type chemotherapy (n=26; 50%) or a standard gynecologic regimen (n=26; 50%). Three-quarters of tumors were early-stage (I or II), 68% grade 1 or 2 and 88% of patients had no gross residual disease after surgery. Patients receiving gastrointestinal-type chemotherapy were more likely to receive bevacizumab (50% vs. 4%; <i>P</i> &lt; .001), but there were no other differences in clinical or demographic characteristics. Unadjusted overall survival analyses showed that gastrointestinal-type chemotherapy was associated with better overall survival (HR 0.2, 95% CI 0.1–0.8), as were early stage tumors and having no gross residual disease. </p> </div><div class="section"> <a class="named-anchor" id="S4"> <!-- named anchor --> </a> <h5 class="title" id="d606809e237">Conclusion</h5> <p id="P4">Gastrointestinal-type chemotherapy with or without bevacizumab was associated with improved survival and should be considered in patients with ovarian mucinous carcinoma requiring adjuvant therapy. </p> </div><p id="P5">Gastrointestinal-type chemotherapy is associated with improved survival in ovarian mucinous carcinoma when compared to standard gynecologic regimens. </p>